Why the study?
RNA viral infections cause epidemics and pandemics lacking specific preventive and therapeutic regimens, prompting exploration of RdRP as an antiviral target.
Design
Review
Key result
Nucleoside analogs inhibit viral RNA-dependent RNA polymerases through diverse mechanisms, including delayed chain termination (remdesivir), immediate termination (sofosbuvir), and lethal mutagenesis (molnupiravir).
Authors
Loading...
May guide nucleoside analog design for viral RdRP inhibition; leaves open clinical validation in randomized trials.
This review highlights the molecular mechanisms by which nucleoside analogs inhibit viral RNA-dependent RNA polymerases, facilitating rational antiviral drug design.
Sailen Barik (2022) conducted a review in RNA virus infections. Nucleoside analogs (remdesivir, sofosbuvir, molnupiravir) was evaluated. Nucleoside analogs inhibit viral RNA-dependent RNA polymerases through diverse mechanisms, including delayed chain termination (remdesivir), immediate termination (sofosbuvir), and lethal mutagenesis (molnupiravir).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: